Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

d July 2011.
  • Data on file.

  • Novartis Media RelationsMedia only:Investors only:Nicole Riley

    Richard JarvisNovartis Oncology

    Novartis CorporationP: +1 862 778 3110

    P: +1 212 830 2433Dana Kahn Cooper

    investor.relations@novartis.comP: +1 732 817 1800F: +1 732 817 1834For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis

    For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.


    '/>"/>

    SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
    2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
    3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
    4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
    5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
    6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
    7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
    8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
    9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
    10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
    11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... plc (NYSE: ACT ), a leading global pharmaceutical company, ... of Actavis, will provide an overview and update of the ... Conference in Rancho Palos Verdes, Calif. ... The presentation will take place on Wednesday, June 10, 2015 ... Rancho Palos Verdes, Calif.  To access a ...
    (Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ... "The Future of Pharmaceutical Outsourcing" report to ... a desperate need to develop better drugs with ... have been increasingly utilizing external resources to increase ... streamlining their internal operation. Their outsourcing demands and ...
    (Date:6/3/2015)... , June 3, 2015 MEDTEC China South 2015 came ... of MEDTEC China 2015, MEDTEC China South has been recognized ... out as a key event for the medical device manufacturing ... years of challenges, this year marks the successful return of the ... after the event first debuted there in 2005. ...
    Breaking Medicine Technology:Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2The Future of Pharmaceutical Outsourcing: 2015 Report 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3
    ... ACR70 Results, SOUTH SAN FRANCICSO, Calif., Dec. ... today announced that its oral syk,kinase inhibitor, R788 ... Rheumatoid Arthritis (RA) patients in a,recently completed Phase ... and 150mg po bid (orally, twice daily), showed ...
    ... BioForm Medical,Inc. (Nasdaq: BFRM ) today announced ... of nasolabial fold treatments,reporting higher patient satisfaction with ... either Juvederm(TM) or Perlane(R). The,results of this study ... of,the Journal of Dermatologic Surgery, a peer-reviewed publication ...
    Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 2Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 3Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 4Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 5Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 6
    (Date:6/3/2015)... Johnson & Johnson and its Janssen ... resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) filed by ... used to market the antipsychotic drug. Court records ... Arkansas Attorney General moved to dismiss the case on ... settlement amounts to just a fraction of the $1.2 ...
    (Date:6/3/2015)... 2015 The National Resident Matching Program ... C. Savoia, M.D., Dean of Medical Education at the University ... Chair on July 1. , “It is an ... Resident Matching Program,” said Dr. Savoia. “NRMP’s goal is ... medical students with training programs, and I welcome the opportunity ...
    (Date:6/3/2015)... On the heels of a report predicting bioinformatics ... click here to review news coverage about the report ... has the talent to become a world-leading center of the ... biological data are collected and analyzed to help scientists discover ... elements of a perfect storm for bioinformatics leadership,” said Dr. ...
    (Date:6/3/2015)... 2015 Horizon Blue Cross Blue Shield of ... one of the nation’s top employers for diverse managers and ... its national list of Best Places for Diverse Managers and ... 1 Regional Company. This is the sixth consecutive year ... for its diverse workplace policies and programs. , Companies are ...
    (Date:6/3/2015)... VeoMed and Decker are announcing ... mobile access to premier Continuing Medical Education (CME) ... (MOC) activities. , Through this ... Decker’s extensive lists of physicians, residents, nurses and ... VeoMed’s premier online and live-streamed courses. Healthcare professionals ...
    Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2
    ... Speaker Nancy Pelosi,delivered remarks this morning at the ... members of Congress, and hundreds of,children and seniors. ... full,funding of the State Children,s Health Insurance Program ... ask me what the three most important issues ...
    ... BETHESDA, Md., Sept. 6 Montana native and health ... Center Billings, MT, has been,installed to the post ... Health Centers (NACHC). Ceremonies took place at NACHC,s ... in Dallas, TX,which drew thousands of health center ...
    ... to make open-heart,surgery a minimally invasive procedure ... of Health Bioengineering Research Partnership award.,Professor Pierre ... surgeon Pedro del Nido, M.D., at Children,s ... Inc. (Van Nuys,CA) will collaborate to develop ...
    ... finds it brings the patient real benefit, too , ... partners with Alzheimer,s disease report better physical health if ... shows. , "Preserving the health of spouse caregivers through ... disease, as caregivers who are in poor health are ...
    ... 6 In response to,reports about the potential closure ... today reassured employees that the,civil section of the facility ... of closing the civil section of Warren,State Hospital and ... in,which residents and counties have come to depend," said ...
    ... on most common cause of inherited mental ... impairment and Parkinson-like syndrome, SAN FRANCISCO, ... California, Davis, School of Medicine and the M.I.N.D.,Institute, in collaboration ... Interdisciplinary Research Consortium grant from,the National Institutes of Heath, the ...
    Cached Medicine News:Health News:Pelosi: SCHIP Bill a Giant Step for America's Children 2Health News:Montana Health Care Leader Elected Board Chair of National Association 2Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2Health News:PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors 2Health News:$21.8 Million NIH Grant for Fragile X Research 2Health News:$21.8 Million NIH Grant for Fragile X Research 3Health News:$21.8 Million NIH Grant for Fragile X Research 4
    Egg-Shaped Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be e...
    ... Discrete Technology Coronary Stent System provides ... Secure Technology stent retention system features ... encapsulate the stent for added security ... to minimize balloon overhang and to ...
    Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
    For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
    Medicine Products: